Loading market dashboard
United Therapeutics Corporation
UTHRHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons made a prodigious investment in the memory company as far back as 2013 – when it was trading at approximately $18 – and saw the equity rise almost exactly 5,000% since.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST, at the Jefferies Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archive.
United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
/PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST, at the RBC Capital Markets Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.
United Therapeutics shares rise after Q1 earnings miss estimates as investors focus on Tyvaso IPF data and ralinepag's blockbuster potential.
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology earnings and forecasts that destroyed Wall Street estimates. All of the major indices were once again printing new highs as investors cheered the potential for... Here Are Thursday's Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript
United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. “In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE O.
Evaluate the expected performance of United Therapeutics (UTHR) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor Raymond Dwek, C.B.E., F.R.S., as a member of the Board of Directors will expire at the 2026 Annual Meeting of Shareholders, scheduled for June 26, 2026. Prof. Dwek, who is widely recognized for his pioneering work at Oxford University in the field of glycobiology, joined the United Therapeutics Board in 2002.
Comerica Bank boosted its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 2.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,683 shares of the biotechnology company's stock after buying an additional 3,731 shares during the period.
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 364 shares of the company's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40. Following the transaction, the chief financial officer owned 18,996 shares in the company, valued
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics is rated a long-term Buy, driven by its pioneering efforts in xenotransplantation and organ manufacturing. Current revenue relies heavily on treprostinil-based therapies, but future growth is expected from FDA-approved lab-grown organs by 2030. Patent expirations and competition present near-term risks, yet margins have improved and the company remains well-positioned for transition.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026 at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, May 6, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of the webc.
Asset Management One Co. Ltd. decreased its stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 5.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,267 shares of the biotechnology company's stock after selling 1,243 shares during the
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions taking place April 22-25, 2026, in Toronto, Canada. "The data from ARTISAN and PHINDER suggest that earlier detection and in.
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Christopher Patusky sold 1,000 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $578.88, for a total transaction of $578,880.00. Following the transaction, the director directly owned 1,490 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $576.82, for a total value of $4,787,606.00. Following the transaction, the executive vice president directly owned 45,172 shares of the
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $580.36, for a total transaction of $5,513,420.00. Following the completion of the transaction, the chief executive officer owned 40,513
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors bought 15,930 call options on the company. This represents an increase of 665% compared to the average volume of 2,083 call options. United Therapeutics Stock Performance United Therapeutics stock opened at $588.38 on Friday.
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the company's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company,
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $574.86, for a total value of $5,461,170.00. Following the transaction, the chief executive officer directly owned 40,513 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $569.28, for a total transaction of $5,408,160.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the firm's stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $580.45, for a total value of $5,514,275.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $558.41, for a total transaction of $5,304,895.00. Following the transaction, the chief executive officer directly owned 40,513 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational miroliverELAP®, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood cir.
BAM Wealth Management LLC purchased a new position in United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 886 shares of the biotechnology company's stock, valued at approximately $432,000. Other hedge funds have
Element Squared LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,027 shares of the biotechnology company's stock, valued at approximately $2,449,000. United Therapeutics accounts for 1.3%
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total value of $5,525,485.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $590.59, for a total transaction of $5,610,605.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the
Brookstone Capital Management grew its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 25.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,622 shares of the biotechnology company's stock after purchasing an additional 1,342 shares during the quarter. Brookstone
United Therapeutics Corporation maintains a Strong Buy rating after a second phase 3 win for nebulized Tyvaso in idiopathic pulmonary fibrosis [IPF]. UTHR achieved superior FVC improvement in TETON-1 [130.1 mL] versus TETON-2 [95.6 mL], both statistically significant, supporting sNDA submission for IPF by summer of this year. Priority Review will be sought for Tyvaso in IPF, with further expansion targeted via ongoing TETON-PPF for progressive pulmonary fibrosis.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exchange Traded Concepts LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 31.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,864 shares of the biotechnology company's stock after purchasing an additional 1,164 shares
United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA filing.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
